Research Interests
My research focuses specifically on improving clinical outcomes for lymphoma patients with interventions in exercise, survivorship, and financial toxicity. I also participate in a number of treatment related clinical trials to help patients access the latest available treatments and continue to improve our treatment options for these patients.
I thoroughly enjoy each opportunity for patient care, and my patients are truly the driver for my research questions and interests. Overall, I hope to 1) provide each patient with a personalized experience that optimizes his or her own care and 2) advance the field of survivorship and chronic cancer management to inform the overall care of these patients and ultimately improve their outcomes.
Selected Grants
Randomized Controlled Trial of a Hybrid-Delivered Cognitive Behavioral Symptom Management and Activity Coaching Intervention for Stem Cell Transplant Patients
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter?s Syndrome
Clinical TrialPrincipal Investigator · Awarded by Genmab US, Inc. · 2023 - 2028Loxo: III Trial of Fixed Pirtobrutinib + Vene and Rituximab vs Vene + Rituximab in CLL/SLL
Clinical TrialPrincipal Investigator · Awarded by Loxo Oncology, Inc. · 2022 - 2027US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITITM
ResearchPrincipal Investigator · Awarded by Innate Pharma · 2021 - 2026DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PROSPECTIVE PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF PANZYGA IN PRIMARY INFECTION PROPHYLAXIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA ("PRO-SID" study)
Clinical TrialPrincipal Investigator · Awarded by Octapharma AG · 2020 - 2023Randomized Controlled Trial of a Hybrid-Delivered Cognitive Behavioral Symptom Management and Activity Coaching Intervention for Stem Cell Transplant Patients
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter?s Syndrome
Clinical TrialPrincipal Investigator · Awarded by Genmab US, Inc. · 2023 - 2028Loxo: III Trial of Fixed Pirtobrutinib + Vene and Rituximab vs Vene + Rituximab in CLL/SLL
Clinical TrialPrincipal Investigator · Awarded by Loxo Oncology, Inc. · 2022 - 2027US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITITM
ResearchPrincipal Investigator · Awarded by Innate Pharma · 2021 - 2026DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PROSPECTIVE PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF PANZYGA IN PRIMARY INFECTION PROPHYLAXIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA ("PRO-SID" study)
Clinical TrialPrincipal Investigator · Awarded by Octapharma AG · 2020 - 2023A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies
Clinical TrialPrincipal Investigator · Awarded by MEI Pharma, Inc. · 2020 - 2023Exercise training to promote improved immune resilience in adults with chronic lymphocytic leukemia - a randomized control trial
Clinical TrialCollaborator · Awarded by American Society of Hematology · 2020 - 2021External Relationships
- BeiGene
- OncLive
- TG Therapeutics, IC, New York NY
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.